Cargando…
Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory Merkel cell carcinoma patient
Autores principales: | Yeakel, John, Kannan, Aarthi, Rattigan, Nicole Hook, Yamamoto, Maki, Aleshin, Alexey, Harris, Jeremy P., Gao, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626794/ https://www.ncbi.nlm.nih.gov/pubmed/34869814 http://dx.doi.org/10.1016/j.jdcr.2021.10.025 |
Ejemplares similares
-
BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2021) -
Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts
por: Fang, Bin, et al.
Publicado: (2020) -
BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022) -
Evolving Applications of Circulating Tumor DNA in Merkel Cell Carcinoma
por: Prakash, Varsha, et al.
Publicado: (2023) -
Bespoke Dual Resonance
por: Cheung, Clifford
Publicado: (2023)